Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04558450
Recruiting Not applicable

Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)

NCT04558450 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Not applicable
Started
2020-09-21
Last updated
2021-11-22

Condition(s) studied

Covid19Arterial StiffnessEndothelial DysfunctionDiastolic Dysfunction

Investigational drug(s) / intervention(s)

carotid-femoral pulse-wave velocity

carotid-femoral pulse-wave velocity: early vascular aging tests

Study summary

The purpose of the study is to evaluate the presence of early vascular aging 6 months and 12 months after COVID-19 infection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * age \>18 years, both sexes; * written informed consent; * affiliation to a social security regime; * a recent diagnosis of COVID19 (6±3 months) proven by PCR or serology (for group 1,2,3) * hospitalization in intensive care unit for COVID19 (for group 1) * hospitalization in a medicine unit for COVID19 (for group 2) * no hospitalization for COVID19 or hospitalization less than 24h (for group 3) * a negative test for SARS-nCOV2 infection (PCR or serology)(for group 4) Exclusion Criteria: * Age \<18 years * Inability to express consent of the study * Diseases carrying out a life -expectancy \<1 year according to clinical judgment * Pregnancy and breastfeeding * Foreseen inability to attend scheduled visits

Primary outcome measure(s)

  • PWV — 6 months after COVID19 infection
    carotid-femoral pulse wave velocity measured by application tonometry
  • PWV — 12 months after COVID19 infection
    carotid-femoral pulse wave velocity measured by application tonometry
  • PWV change — difference between PWV at 12 and 6 months after COVID19 infection
    carotid-femoral pulse wave velocity measured by application tonometry

Trial sites (3)

FacilityCityRegionStatus
CHRU Nancy Nancy France Recruiting
Hôpital Européen Georges Pompidou - APHP Paris France Recruiting
CHU Rouen Rouen France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Prospective Longitudinal Cohort Study of Vasculitis Patients Recruiting
Quality of Life of Caregivers Supporting an Older Adult With Cancer Starting soon
Study of the Prevalence of Endometriosis and Adenomyosis Recruiting
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy Recruiting
Certolizumab in Recurrent Implantation Failure (RIF) Recruiting

Other trials for the same condition

Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal Recruiting
COVID-19 Serology and Immunosenescence Active, not recruiting
Physiopathology and Sequelae of COVID-19 Infection Active, not recruiting
Risk Markers of Arterial Aging. The Paris Prospective Study III-2 Recruiting
Narrow Band Imaging Bronchoscopy During SARS-CoV2 Infection Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04558450 on ClinicalTrials.gov ↗ ← All trials in France